Patients characteristics
NSCLC, pneumonitis, death, tumor, anaplastic lymphoma
PNEUMONITIS, TUMOR, METASTASIS, LUNG CANCER, NSCLC, ONCOLOGY
This study ultimately included 752 patients with advanced NSCLC treated with ICIs between January 1, 2018, and December 30, 2021, of whom 60 were diagnosed with CIP, for an incidence of 8.0% (60/752). All patients were divided into the training set and testing set in a 7:3 ratio (526 patients and 226 patients, respectively). Finally, 42 patients in the training set were confirmed to have CIP, while 18 patients in the testing set were diagnosed. The procedure for patient selection is shown in Figure Flowchart of patient selection.The baseline characteristics of patients in the training set and testing set are shown in Table Baseline characteristics of patients in training and testing set.Abbreviations: AEC, absolute eosinophil count; ALC, absolute lymphocyte count; ALK, anaplastic lymphoma kinase; ANC, absolute neutrophil count; CIP, checkpoint inhibitor‐related pneumonitis; CRP, C‐reactive protein; ECOG PS, Eastern Cooperative Oncology Group, performance status; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; NLR, neutrophil to lymphocyte ratio; NSCLC, non‐small cell lung cancer; PD‐1, programmed cell death protein‐1; PD‐L1, programmed cell death ligand‐1; TNM, tumor node metastasis; TPS, tumor proportion score; WBC, white blood cell count.